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Abstract Aggregated alpha-synuclein is the main com-
ponent of Lewy bodies, intraneuronal deposits observed in
Parkinson’s disease and dementia with Lewy bodies. The
objective of the study was to identify surface-exposed
epitopes of alpha-synuclein in vitro and in vivo formed
aggregates. Polyclonal immunoglobulin Y antibodies were
raised against short linear peptides of the alpha-synuclein
molecule. An epitope in the N-terminal region (1–10) and
all C-terminal epitopes (90–140) were found to be exposed
in an indirect enzyme-linked immunosorbent assay
(ELISA) using recombinant monomeric, oligomeric, and
fibrillar alpha-synuclein. In a phospholipid ELISA, the
N-terminus and mid-region of alpha-synuclein (i.e., 1–90)
were associated with phosphatidylserine and thus occluded
from antibody binding. The antibodies that reacted most
strongly with epitopes in the in vitro aggregates (i.e., 1–10
and epitopes between positions 90–140) also labeled alpha-
synuclein inclusions in brains from transgenic (Thy-1)-
h[A30P] alpha-synuclein mice and Lewy bodies and Lewy
neurites in brains of patients with alpha-synucleinopathies.
However, differences in reactivity were observed with the
C-terminal antibodies when brain tissue from human and
transgenic mice was compared. Taken together, the study
shows that although similar epitopes are exposed in both
in vitro and in vivo formed alpha-synuclein inclusions,
structural heterogeneity can be observed between different
molecular species.
Keywords Parkinson’s disease  Dementia with Lewy
bodies  Alpha-synuclein  Epitope mapping
Introduction
The alpha-synucleinopathies are a subset of neurodegen-
erative diseases that include Parkinson’s disease (PD),
dementia with Lewy bodies (DLB), multiple system atro-
phy (MSA), and the Lewy body variant of Alzheimer’s
disease (Goedert 2001). The common pathological feature
of the alpha-synucleinopathies is the presence of insoluble
cytoplasmic aggregates of alpha-synuclein, termed Lewy
bodies and Lewy neurites (Spillantini et al. 1997). In PD,
the inclusions are mainly found in dopaminergic neurons in
the substantia nigra and other subcortical regions, while in
DLB, they are also located in the cerebral cortex (Spil-
lantini et al. 1997, 1998). In MSA, the aggregates are
predominantly found in oligodendrocytes and are then
referred to as glial cytoplasmic inclusions (Papp et al.
1989).
Alpha-synuclein consists of three distinct structural
domains: a lipid-interacting amino-terminus (1–60), a
hydrophobic mid-region (61–95), and an acidic carboxyl-
terminus with a random coil structure (96–140) (George
et al. 1995). It has been believed that alpha-synuclein
mainly exists as an intrinsically disordered protein, which
adopts an alpha-helical structure upon binding to lipids via
its N-terminus and central region (Davidson et al. 1998).
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The physiological function of alpha-synuclein remains
largely unknown, but increasing evidence suggest that it is
involved in neurotransmitter release (Abeliovich et al.
2000; Nemani et al. 2010). For example, alpha-synuclein
can promote the formation of the soluble N-ethyl-
maleimide-sensitive factor attachment protein receptor
(SNARE) complex by binding phospholipids in the cell
membrane with its N-terminus and synaptobrevin-2 with its
C-terminus (Burre´ et al. 2010).
Further implicating alpha-synuclein misfolding in the
pathogenesis of neurodegenerative diseases, duplications
and triplications of the alpha-synuclein gene (Singleton
et al. 2003; Iba´n˜ez et al. 2004), as well as six different point
missense mutations have been found to cause either PD or
DLB. All the identified point mutations are located in the
N-terminal region of the molecule: A53T (Polymeropoulos
et al. 1997), A30P (Kru¨ger et al. 1998), E46K (Zarranz
et al. 2004), H50Q (Appel-Cresswell et al. 2013), G51D
(Lesage et al. 2013), and A53E (Pasanen et al. 2014).
In the alpha-synucleinopathies, alpha-synuclein forms
oligomers and protofibrils of increasing sizes, ultimately
leading to insoluble fibrils, which constitute the main
component of the Lewy body. Mounting evidence suggests
that the oligomers are the most neurotoxic molecular spe-
cies, as they have been shown to cause cytotoxicity both
in vitro and in vivo (Danzer et al. 2007; Outeiro et al. 2008;
Karpinar et al. 2009; Winner et al. 2011). However, it has
not been fully elucidated which parts of the protein are
involved in the aggregation process and how well alpha-
synuclein aggregates generated in vitro resemble in vivo
formed inclusions.
So far, a pair of studies have been performed using
antibodies recognizing linear epitopes to characterize
structural properties of alpha-synuclein inclusions in the
brains of diseased patients (Giasson et al. 2000; Duda et al.
2002). However, no study has systematically compared
surface-exposed epitopes of in vitro and in vivo formed
alpha-synuclein aggregates. Here, we raised polyclonal
immunoglobulin Y (IgY) antibodies against short linear
epitopes spanning most of the molecule. These antibodies
were used to determine the exposed epitopes of alpha-
synuclein monomers and fibrils generated in vitro, as well
as inclusions in brain tissue sections from a transgenic




The immunizing peptides (10–11 amino acids) were cus-
tom synthetized at Capra Science Antibodies (A¨ngelholm,
Sweden), and the molecular weight of the peptides was
confirmed by mass spectral analysis. The peptides had a
purity of about 90% as determined by analytical HPLC.
The longer peptides (19–26 amino acids) were custom
synthetized at KJ Ross Petersen Aps (Copenhagen,
Denmark).
Antibody Production
Polyclonal IgY antibodies were custom manufactured at
Capra Science Antibodies (A¨ngelholm, Sweden). In short,
the synthetic peptides were linked to keyhole limpet
hemocyanin and two peptides (100 lg each) per chicken
were injected together with Freund’s complete adjuvant
(week 0). Two additional boosts (with 100 lg peptide)
with Freund’s incomplete adjuvant were performed
(weeks 4 and 8). Eggs were then collected and the IgY
fraction was purified, followed by an affinity purification
step where the antigens were covalently immobilized on an
agarose gel and the antibodies were eluted at pH 2.7.
Production and Purification of Recombinant Alpha-
Synuclein
Recombinant wild-type (wt) alpha-synuclein was cloned,
expressed, and purified as previously described (Na¨sstro¨m
et al. 2011). Mutant alpha-synuclein (A30P, E46K and
A53T) was purchased from rPeptide (Athens, GA).
Generation of Alpha-Synuclein Oligomers
and Fibrils
To generate 4-hydroxy-2-nonenal (HNE)-induced alpha-
synuclein oligomers, alpha-synuclein (140 lM) in 50 mM
sodium phosphate buffer pH 7.4 was mixed with HNE
(Cayman Chemical, Ann Arbor, MI) to a final molar ratio
of 30:1 (HNE:alpha-synuclein). The samples were incu-
bated quiescently at 37 C for 24 h, and unbound aldehyde
was removed by a Zeba spin desalting column (Thermo
Fisher Scientific, Waltham, MA) according to the manu-
facturer’s instructions. To generate fibrils, wt and mutant
alpha-synuclein (140 lM) were incubated in Tris buffered
saline (TBS) pH 7.4 in a non-binding polystyrene 96-well
plate with agitation for 7 days at 37 C. The alpha-synu-
clein fibrils were first pelleted by centrifugation at
16,0009g, then re-suspended and washed in TBS and
pelleted again by centrifugation. This procedure was per-
formed twice. The fibrillar content of such samples has
been verified by atomic force microscopy earlier (Na¨sstro¨m
et al. 2011), but to confirm the presence of fibrils in the
pelleted material, 1 ll of sample was dried on a glass slide
that was stained with Congo red (Sigma-Aldrich, St. Louis,
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MO). All fibrillar samples exhibited typical apple-green
birefringence when viewed under polarized light.
Indirect Enzyme-Linked Immunosorbent Assay
(ELISA)
A 96-well high-binding polystyrene plate (Corning Inc.,
Corning, NY) was coated with 50 ng antigen (synthetic
peptides, monomeric or fibrillar alpha-synuclein) and was
incubated overnight at 4 C. After blocking for 2 h with
phosphate buffered saline (PBS) supplemented with 1%
bovine serum albumin (BSA, Sigma-Aldrich) and 0.15%
kathon (Dow Chemical Company, Midland, MI), the anti-
bodies were incubated at a concentration of 0.5 lg/ml for
1 h in PBS with 0.1% BSA and 0.05% Tween-20 (Sigma-
Aldrich). An HRP-bound secondary anti-chicken goat
antibody (Jackson ImmunoResearch Laboratories Inc.,
West Grove, PA) was incubated for 1 h at 0.08 lg/ml in
the PBS buffer used for the primary antibody step. The
reaction was developed with 100 ll K-Blue Aqueous TMB
substrate (Neogen Corporation, Lansing, MI) and stopped
with the addition of 100 ll 1 M sulfuric acid (Sigma-
Aldrich). Between every step, the wells were washed five
times with PBS with 0.1% Tween 20 and 0.0075% kathon.
The absorbance was measured at 450 nm using an Infinite
M200 Pro microplate reader (Tecan, Ma¨nnedorf, Switzer-
land). The signal of the blank (no coated antigen) was
subtracted from the sample signals.
Phospholipid ELISA
1,2-Dioleoyl-sn-glycero-3-phospho-L-serine (DOPS) ELISA
SnoopersTM (Avanti Polar Lipids, Alabaster, AL) 8-well
strips were blocked with 200 ll/well of blocking buffer [1%
fatty acid-free BSA (Sigma-Aldrich) in PBS] at 4 C over-
night. Then, alpha-synuclein samples (50 ng/well) were
incubated in PBS for 3 h with gentle shaking at room
temperature and washed four times with PBS. The anti-
bodies were incubated at a concentration of 0.5 lg/ml in
blocking buffer for 1 h. Following three PBS washes, an
HRP-bound secondary anti-chicken antibody (Jackson
ImmunoResearch Laboratories Inc.) was incubated for 1 h at
0.08 lg/ml in blocking buffer. After three PBS washes, the
reaction was developed with TMB substrate (Neogen Cor-
poration) and 1 M sulfuric acid (Sigma-Aldrich). The
absorbance was measured at 450 nm using an Infinite M200
Pro microplate reader (Tecan). The signal of the blank (no
antigen) was subtracted from the sample signal.
Transgenic Alpha-Synuclein Mouse Model
Formalin-fixed and paraffin-embedded brain tissues from
homozygous (Thy-1)-h[A30P] alpha-synuclein mice
(Kahle et al. 2000) were used (n = 4; 16, 18, 19, and
22 months of age). The tissue was sagittally sectioned
(3 lm). Brain tissue from wt mice (C57BL/6) was used as
a negative control (18 months of age). All animal proce-
dures with the (Thy-1)-h[A30P] alpha-synuclein mouse
have been approved by the regional board of Tu¨bingen,
Germany. Animal procedures with the wt mice have been
approved by the animal ethics committee of Uppsala,
Sweden.
Human Brain Tissue
The brain samples were obtained from The Netherlands
Brain Bank (NBB), Netherlands Institute for Neuroscience,
Amsterdam (open access: www.brainbank.nl), project
number 848. All the materials were collected from donors
from whom a written informed consent for a brain autopsy
and the use of the material and clinical information for
research purposes had been obtained by the NBB. Sub-
stantia nigra samples from four patients [one PD, one DLB,
and two Parkinson’s disease with dementia (PDD)] and one
neurologically normal control were used (Table 1).
Immunohistochemistry of Mouse and Human Brain
Tissue
Paraffin sections were deparaffinized through ethanol baths
of decreasing concentration (99.9–70%) and then washed
with distilled water. The sections were pretreated with
proteinase K (Life Technologies, Carlsbad, CA) at 50 lg/
ml in a buffer containing 10 mM Tris–HCl, 100 mM NaCl,
0.1% Nonidet-P40 (United States Biochemical Corpora-
tion, Cleveland, OH) at pH 7.8 and 37 C for 5 min.
Additionally, the human tissue was microwaved in pre-
heated 25 mM citrate buffer for 15 s and allowed to cool
down at room temperature for 40 min. All sections were
then permeabilized with 0.4% Triton X-100 (Sigma-
Aldrich) in TBS for 10 min and treated with 0.3% H2O2 for
5 min to block endogenous peroxidase reactivity. The
sections were blocked with Background Sniper (Biocare
Medical, Concord, CA) and incubated at 4 C overnight
Table 1 Summary of information of the patient material used in the
study
Case# 1 2 3 4 5
Age 80 80 61 81 80
Sex F F M M M
Dx PDD DLB PDD PD NN
PMD 5:15 5:00 5:00 4:30 7:00
Dx diagnosis, PD Parkinson’s disease, PDD Parkinson’s disease
dementia, DLB dementia with Lewy bodies, NN neurologically nor-
mal, PMD postmortem delay
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with the IgY antibodies at a concentration of 0.5 lg/ml.
Detection was performed using a biotinylated secondary
anti-chicken (1.5 lg/ml, Jackson ImmunoResearch Labo-
ratories Inc.), followed by incubation with Streptavidin-
HRP (1:30, 3310-9, Mabtech AB, Nacka, Sweden). The
signal was visualized using the NovaRed substrate kit
(Vector Laboratories). The sections were counterstained
with hematoxylin (Histolab, Gothenburg, Sweden), dehy-
drated and mounted with DPX (VWR, Stockholm, Swe-
den). As a negative control, sections were incubated with
secondary antibody alone.
Neuropathological Analysis of Mouse and Human
Brain Tissue
Two independent assessors analyzed immunohistochemi-
cally stained sections semi-quantitatively in a blinded
manner. The intensity of the staining was scored on a
predetermined scale of 0–3 (0 = no signal, 1 = overall
faint signal, orange/yellow-colored LB in human tissue,
2 = overall positive signal, red-colored LB in human tis-
sue, 3 = very strong signal, dark red/brown-colored LB in
human tissue), and scores were averaged. The differences
between mouse and human brain were assessed by a two-
way ANOVA and Bonferroni post hoc tests.
Results
Characterization of Immunoglobulin Y Antibodies
In order to determine the surface-exposed epitopes of
alpha-synuclein, we generated 18 polyclonal IgY antibod-
ies against short linear peptides spanning most of the alpha-
synuclein molecule (Fig. 1). We chose to generate chicken
IgY antibodies because of the increased phylogenetic dis-
tance between chicken and humans compared to other
mammalian species typically used for antibody production
(e.g., rabbit) (Hadge and Ambrosius 1984). The sequence
identity of chicken alpha-synuclein and human alpha-
synuclein is 86.7% compared to 95% between rabbits and
humans, which could potentially increase the immuno-
genicity of the alpha-synuclein peptides. The antibodies
were affinity purified against their respective immunizing
peptide and showed similar reactivity against them as
observed by indirect ELISA (Fig. 2a).
To probe the specificity of the antibodies further, they
were used in an indirect ELISA against longer peptides
covering different parts of alpha-synuclein (10–34, 32–50,
45–65, 91–115, 101–125, and 115–140) (Fig. 2b). Eight of
the antibodies (22–31, 35–44, 54–63, 59–68, 74–83,
101–110, 121–130, and 126–135) also recognized peptides
that did not contain their immunizing sequence and
therefore were eliminated from the study.
Indirect ELISA of In Vitro Generated Aggregated
Species of Alpha-Synuclein
First, we mapped the surface-exposed epitopes of recom-
binant monomeric and oligomeric alpha-synuclein
(Fig. 3a). All antibodies recognized monomeric alpha-
synuclein, but 49–58 and 64–73 reacted to a lesser extent.
The N-terminal antibody 1–10 reacted with oligomers,
while 49–58 did not. In the mid-region, 64–73 was nega-
tive against oligomers and 79–88 was positive. The
C-terminal antibodies (90–140) all recognized oligomeric
alpha-synuclein.
Point mutations in the alpha-synuclein (SNCA) gene
enhance aggregation and cause early-onset PD or DLB
(Polymeropoulos et al. 1997; Kru¨ger et al. 1998; Conway
et al. 2000; Zarranz et al. 2004; Greenbaum et al. 2005).
We generated fibrils consisting of either wild-type (wt)
protein or the three mutants (A30P, E46K and A53T) and
analyzed them using indirect ELISA (Fig. 3b). The overall
reaction pattern for the different fibrils was similar, where
the antibody against 1–10, as well as the C-terminal (i.e.,
90–140) antibodies showed the highest signals. Overall, the
strongest immunoreactivity was observed for wt and A30P
fibrils, whereas the lowest signals were seen with the A53T
fibrils.
Alpha-synuclein interacts with anionic phospholipids in
the neuronal membrane, and the binding has been sug-
gested to be facilitated by the N-terminal part of the protein
(Davidson et al. 1998). To determine the lipid-binding
ability of the various alpha-synuclein species and to discern
the membrane-associated epitopes, an indirect
Fig. 1 Sequence of
immunizing peptides and
human alpha-synuclein with its
three structural regions: the
N-terminus (1–60 red), the mid-





phospholipid ELISA was used. Monomeric and fibrillar
(wt) alpha-synuclein were incubated on a plate pre-coated
with phosphatidylserine, and the interaction was probed
with the antibodies (Fig. 3c). Antibodies against the
C-terminus (96–140) reacted with monomeric alpha-synu-
clein, and to a lesser extent fibrils, with the exception of the
antibody 111–120 that reacted to fibrils equally well. In
contrast, the antibodies against the N-terminus and mid-
region (i.e., 1–95) did not react with monomers or fibrils
(with the exception of 1–10 that recognized fibrils), indi-
cating that this region of the molecule was indeed inter-
acting with phosphatidylserine.
Immunohistochemistry of Mouse and Human Brain
Next, we wanted to analyze exposed epitopes of in vivo
deposited alpha-synuclein aggregates by performing
immunohistochemistry with the antibodies on formalin-
fixed and paraffin-embedded tissue sections of (Thy-1)-
h[A30P] alpha-synuclein transgenic mouse brain and sec-
tions from the substantia nigra of PD, PDD, and DLB
patients. We performed a proteinase K treatment to digest
non-fibrillar alpha-synuclein (Giasson et al. 2001; Miake
et al. 2002; Neumann et al. 2002) and to ensure that the
aggregates observed in both mouse and human tissue were
comparable.
The (Thy-1)-h[A30P] alpha-synuclein transgenic mouse
model presents cognitive decline at 12 months of age,
whereas PD-like motor symptoms can be observed at
17 months (Kahle et al. 2000; Schell et al. 2009). Brain
sections from four mice at or after onset of motor symptom
were analyzed. Alpha-synuclein aggregates could be
observed in the cerebellum, mid-brain, pons, medulla and
to a lesser extent in the cortex. Four types of alpha-synu-
clein aggregates could be distinguished: (1) small, dotted
grain-like intracellular aggregates, which were the most
abundant in all brain regions; (2) Lewy-neurite-like elon-
gated structures, which sometimes accompanied the grain-
like staining; (3) Lewy body-like inclusions, which could
occasionally be observed, most frequently in the cerebel-
lum, and (4) diffuse nuclear and cytoplasmic accumulation
of alpha-synuclein, which was predominantly observed in
the cerebellum and mid-brain (Fig. 4). The highest
immunoreactivity was observed with the C-terminal epi-
tope 96–105. The N-terminal antibody 1–10 and C-termi-
nal antibodies 90–100, 106–115, 111–120, 116–125, and
Fig. 2 Indirect ELISA
characterizing the generated
antibodies. The immunizing
peptides were coated onto a
microtiter plate and analyzed
with the corresponding antibody
(a). Peptides of 19–26 amino
acids were coated onto a plate
and analyzed with the
antibodies to further test their
specificity. Underlined
antibodies showed no cross-
reactivity and were selected for
the following experiments (b).
Error bars represent the
standard error of the mean
(SEM), and each experiment





131–140 also stained the described structures, with variable
intensities. The antibody against 131–140, in particular,
showed less immunoreactivity. No staining was observed
with the antibodies 49–58 and 64–73, and very faint
staining with 79–88 could be observed.
In the human PD, DLB, and PDD brain tissue, 1–10 and
the C-terminal antibodies 111–120 and 116–125 showed
the highest reactivity and stained both Lewy bodies and
Lewy neurites (Fig. 5). The rest of the C-terminal anti-
bodies (90–100, 96–105, 106–115, and 131–140) produced
a weaker staining of inclusions. No immunoreactivity of
Lewy body pathology was detected with antibodies rec-
ognizing epitopes 49–58, 64–73, and 79–88, which corre-
spond to the latter part of the N-terminus and mid-region of
alpha-synuclein. No differences were observed amongst
tissue from patients with different alpha-synucleinopathies
(i.e., PD, DLB, and PDD).
The staining was semi-quantitatively analyzed by visual
scoring between 0 and 3 by two blinded independent
assessors (Fig. 6). Significant differences were observed
between the intensity of the staining of the transgenic mice
and the diseased human brains by the 96–105, 116–125,
and 131–140 antibodies.
Discussion
In Lewy body disorders, the alpha-synuclein protein loses
its native structure and aggregates as insoluble Lewy
bodies and Lewy neurites (Spillantini et al. 1997). The
fibrillation of alpha-synuclein has been studied to a great
extent in vitro. However, a wide range of heterogeneous
structures is formed during the aggregation of recombinant
alpha-synuclein, and it is uncertain how well they reflect
the aggregates formed in vivo. With the aim to identify
similarities and differences of in vitro and in vivo formed
alpha-synuclein aggregates, we generated 18 polyclonal
antibodies against peptides covering most of the alpha-
synuclein sequence. However, when the specificity of the
antibodies was tested, we observed that eight of the anti-
bodies also reacted with alpha-synuclein epitopes outside
their immunizing sequence and hence they were omitted
from the study due to the unspecific binding. In previous
studies (Giasson et al. 2000; Duda et al. 2002), antibodies
recognizing linear epitopes have been used to characterize
alpha-synuclein aggregates, but compared to the present
investigation, fewer epitopes were studied and mostly
human material was analyzed.
In agreement with the structure of a disordered protein,
recombinant monomeric alpha-synuclein reacted with all
the antibodies; however, the 1–10 and all C-terminal
antibodies showed higher reactivity. In vitro generated
fibrils of alpha-synuclein have been shown to contain a
beta-sheet-rich core (Heise et al. 2005; Chen et al. 2007),
spanning approximately residues 35–96 as observed by
nuclear magnetic resonance spectroscopy, although the
exact length of the core varies amongst studies (Vilar et al.
2008; Tuttle et al. 2016). In agreement with this model, the
fibrils analyzed by the ELISA showed that epitopes 49–58
and 64–73 were not accessible, and presumably hidden in
the core of the fibril structure. The exposed epitopes in the
oligomers were similar to those in the fibril, with the
exception of 79–88, which was positive in the oligomers
but only weakly reactive in the fibrils. The alpha-synuclein
Fig. 3 Indirect ELISA. The antibodies were used to analyze surface-
exposed epitopes of monomeric and oligomeric alpha-synuclein
(a) and wt, A30P, E46K, and A53T alpha-synuclein fibrils (b).
Monomeric and fibrillar alpha-synuclein were incubated in a
precoated phosphatidylserine microtiter plate for an indirect phos-
pholipid ELISA (c). The error bars represent the SEM. Each
experiment was performed three times (except in the phospholipid
ELISA; n = 2) with sample duplicates
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Fig. 4 Representative images of immunohistochemical staining of (Thy-1)-h[A30P] alpha-synuclein transgenic (Tg) mouse cerebellum. Non-Tg
(non-transgenic). Scale bar 20 lm
Fig. 5 Representatitve images of immunohistochemichal staining of substantia nigra brain tissue from a PDD patient and non-diseased (ND)
brain. Arrows indicate Lewy bodies and arrowheads indicate Lewy neurites. Scale bar 20 lm
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mutations A30P, E46K, and A53T have been shown to
oligomerize faster than the wt protein in vitro (Conway
et al. 2000; Greenbaum et al. 2005). Furthermore, atomic
force microscopy studies indicate that the fibrils generated
with these alpha-synuclein mutations may exhibit struc-
tural heterogeneity compared to fibrils formed by wt pro-
tein (van Raaij et al. 2006). However, in the current study,
the surface-exposed epitopes of A30P, E46K, and A53T
fibrils did not differ to any large degree; suggesting that
although mutant alpha-synuclein may aggregate faster than
wt protein, the fibrils formed exhibit a similar structure.
Alpha-synuclein exists in equilibrium between a
cytosolic and a membrane bound state in vivo (Davidson
et al. 1998). The seven imperfect repeats (KTKEGV)
located in the N-terminus exhibit a variation in
hydrophobicity that is typical of the amphipathic lipid-
binding a-helical domains of apolipoproteins (George et al.
1995). As lipid binding has been suggested to be an
important factor for the physiological function of alpha-
synuclein, we used a phospholipid ELISA assay to probe
which epitopes interact with phospholipids in different
molecular species of alpha-synuclein. We chose to use a
lipid ELISA assay based on phosphatidylserine due to the
fact that this is a common anionic lipid of eukaryotic cel-
lular membranes and is known to bind to alpha-synuclein
(Davidson et al. 1998; Pranke et al. 2011; Zarbiv et al.
2014). For monomeric alpha-synuclein, only C-terminal
epitopes (i.e., 96–140) were accessible, and this indicates
that the N-terminus and the mid-region of the protein were
indeed lipid bound and hence not available for antibody
binding. Interestingly, wt fibrils also showed a strong
binding to phosphatidylserine, and similar to monomeric
protein, the C-terminus was most accessible to antibody
binding. This suggests that the N-terminus and the mid-
region (i.e., 1–95) are responsible for the interaction with
phosphatidylserine, which is consistent with the previously
mentioned lipid-binding domain of alpha-synuclein. The
surprising finding that the N-terminal part of the fibrils (i.e.,
1–10) was somewhat accessible could most likely be
explained by the fact that as several protofilaments con-
stitute a single fibril, not all their N-terminal parts need to
be associated with lipids in order to facilitate binding. It
should be noted that in the phospholipid ELISA, the
phosphatidylserine molecules are forming a planar layer,
and since alpha-synuclein is highly sensitive to membrane
curvature (Middleton and Rhoades 2010), the exposed
epitopes could potentially vary when bound to cellular
membranes and lipid vesicles.
To the best of our knowledge, no study has compared
alpha-synuclein inclusions in human and mice brain tissue.
Therefore, we used our novel antibodies to analyze the
alpha-synuclein immunoreactivity in the brain of a tg
mouse model overexpressing human A30P mutant alpha-
synuclein (Kahle et al. 2000), as well as in substantia nigra
specimens from patients with alpha-synucleinopathies. The
proteinase K treatment is routinely used to assess fibrillar
alpha-synuclein in tissue (Kramer and Schulz-Schaeffer
2007; Tanji et al. 2010), and it allows us to observe
structures that are similar in compactness and morphology.
In the alpha-synuclein transgenic mice, the most abundant
pathology was found in the brainstem (Neumann et al.
2002; Freichel et al. 2007), where small aggregates were
observed, only occasionally accompanied by larger, more
compact inclusions, similar to those found in human tissue.
Nuclear and cytoplasmic staining of neurons was also
frequently detected with the most reactive antibodies. In
both human and mouse tissue, the strongest reactivity was
observed with antibodies against the 1–10 epitope in the
N-terminus and the C-terminus. However, we found dif-
ferences in the intensity of the staining between these tissue
types for antibodies 96–105, 116–125, and 131–140. Taken
together, these findings indicate that there might be struc-
tural differences between the aggregates formed by human
alpha-synuclein in mice and human brains. Generally, a
greater variability of the overall amount of alpha-synuclein
pathology was observed amongst the mice, but it did not
affect the general staining pattern of the antibodies.
A previous study using monoclonal antibodies that
recognized epitopes between 87 and 140 and two poly-
clonal antibodies that recognized 2–12 (SNL-4) and
104–119 (SNL-1) showed strong staining of Lewy bodies
and neurites in the substantia nigra of PD and DLB patients
(Giasson et al. 2000). The results with the SNL-4 antibody
are comparable to the observations of the 1–10 antibody in
the present study and the SNL-1 is similar to the antibody
111–120, which recognized abundant Lewy body pathol-
ogy. Additionally, Kovacs et al. (2012) generated and
characterized a monoclonal antibody (5G4), which
specifically recognizes amino acids 44–57 and strongly
Fig. 6 Semi-quantitative assessment (0–3) of the intensity of the
immunostaining of four (Thy-1)-h[A30P] alpha-synuclein transgenic
mouse brains and four alpha-synucleinopathy patients. *P\ 0.05;
**P\ 0.001, two-way ANOVA followed by Bonferroni post hoc
test, error bars represent the standard error of the mean (SEM)
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labels alpha-synuclein pathology in human brain tissue. In
contrast, our antibody against epitope 49–58, which recog-
nizes a similar epitope, failed to detect any alpha-synuclein
pathology in both the mice and the human tissue. This sug-
gests that the lack of reaction with one of the IgY antibodies
does not necessarily mean that the entire sequence used to
produce that antibody is hidden. The difference in
immunoreactivity could most likely be explained by the fact
that 5G4 recognizes a slightly different epitope.
Taken together, the present study shows that some parts
of the protein always appear to be exposed on the surface;
specifically, the beginning of the N-terminus and the
entirety of the C-terminus were recognized by the IgY
antibodies in both in vitro monomeric and aggregated
samples, as well as in brain sections. On the other hand,
with the exception of the native protein, most of the mid-
region of aggregated alpha-synuclein was consistently
occluded in aggregated forms, which is in agreement with
the previously mentioned fibril core. However, the finding
that C-terminal epitopes were exposed differently in tg
mice and human tissue also suggests that subtle structural
differences can exist in the alpha-synuclein aggregation
species formed in different organisms.
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